PLoS One
June 18, 2026
Elisa Liberati, Hv Curran, Peter Fonagy et al.
INTRODUCTION: Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) is a potentially transformative intervention for post-traumatic stress disorder (PTSD). Despite encouraging Phase III trial results, the psychological mechanisms underpinning MDMA's therapeutic effects remain insufficiently understood. Existing research on MDMA has emphasised neurobiological processes but has...
Qualitative Health Research
February 17, 2026
Zaynab Khan, Sterre Weaver, Rachael V. Dando et al.
1 citation
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental health. An increasing number of patients are considering alternative approaches to managing their mental health symptoms, such as the psychedelic, psilocybin. A growing number of clinical trials show significant and enduring improvements in mood and...
Drug Science Policy and Law
September 1, 2025
David Nutt, David Erritzøe, Anne Katrin Schlag et al.
9 citations
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...
British Journal of Pharmacology
December 19, 2024
David Nutt, Peter Hunt, Anne Katrin Schlag et al.
21 citations
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use...
Br J Clin Pharmacol
January 17, 2024
Hannah Thurgur, Michael T. Lynskey, Anne Katrin Schlag et al.
7 citations
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
Frontiers in Psychology
May 11, 2023
Hannah Thurgur, Meg J. Spriggs, Ashleigh Murphy-Beiner et al.
13 citations
The field of psychedelic assisted therapy (PAT) is growing at an unprecedented pace. The immense pressures this places on those working in this burgeoning field have already begun to raise important questions about risk and responsibility. It is imperative that the development of an ethical and equitable infrastructure for psychedelic care is prioritized to support this rapid expansion of PAT...
Drug Science Policy and Law
2022
Plinio Ferreira, Adam Winstock, Anne Katrin Schlag et al.
9 citations
The recent surge in recreational (non-medical) use of nitrous oxide (N 2 O, also known as ‘laughing gas’) often by inhaling it from balloons, has attracted the attention of some politicians with calls to control its possession under the United Kingdom (UK) Misuse of Drugs Act 1971 (currently selling, but not possession, for recreational use is controlled under the Psychoactive Substances Act...
Drug Science Policy and Law
2022
Rayyan Zafar, Dustin Sulak, Jaime Brambila et al.
3 citations
A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initially of a titrated high-dose...